Lexicon Pharmaceuticals Inc (LXRX): Lexicon Pharmaceuticals Announces Oral P...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	229
Posts	21457
Boards Moderated	2
Alias Born	08/03/2006

BooDog

Re: None

Wednesday, 10/26/2022 10:48:49 AM

Wednesday, October 26, 2022 10:48:49 AM

Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany:

“Evaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trial”, describes the positive results achieved in this proof-of-concept study and will be given on Saturday, October 29th at 3:25pm CEST/9:25am ET.

“Evaluation of LX9211, a Potent, Selective Inhibitor of AAK1, in Preclinical Models of Spasticity”, describes the effect of LX9211 in reducing spasticity in established animal models and will be given on Monday, October 31st at 3:35pm CET/8:35am ET.

https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-oral-presentations-125900260.html

Looks to be waking up.

LXRX chart

Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis